Hovione to build US plant for Vertex's cystic fibrosis drugs

By Gareth Macdonald

- Last updated on GMT

Hovione facility in East Windsor, New Jersey (picture: Google)
Hovione facility in East Windsor, New Jersey (picture: Google)

Related tags New jersey Pharmacology

Hovione and Vertex Pharma have teamed up to set up a continuous manufacturing facility at the former’s site in New Jersey, US.

The project – which is scheduled to completed before the end of 2017 – is designed to support production of Vertex’s approved medicines.

Vertex’s approved products are the cystic fibrosis dugs Kalydeco (ivacaftor) and Orkambi (ivacaftor/ lumacaftor).

The firm's former product, the hepatitis drug  Incivek (telaprevir) was discontinued in 2014. Vertex cited falling demand for the drug caused by competition from newer hepatitis C treatments.

Continuous manufacturing

The new manufacturing facility in East Windsor, New Jersey will house continuous blending capacity, wet and dry granulation systems, fluid bed drying platforms and tableting and coating technologies.

Filipe Gaspar, VP R&D at Hovione, described continuous manufacturing as “as an important scientific advance and an important advance for patients, as the technology will allow us to run manufacturing and process development in parallel with clinical studies.​”

News of the collaboration follows a few months after Hovione said it would spend $24m (€22m) to expand production capacity and enhance the New Jersey facility’s potent active pharmaceutical ingredient (API) handling capabilities.

The expansion – which is due to be completed early next year – is expected to create 60 jobs.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers